You just read:

Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

May 09, 2018, 03:00 ET